CM Perou - 16Department of Genetics, UNC - Lineberger Comprehensive Cancer Center

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 13 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

13P HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive (HER2+) breast cancer (BC): Implications for treatment stratification

R. Sanchez Bayona, O. Martínez-Sáez, D.R. Romero,E. Segui Solis, E. Carcelero, P. Tolosa Ortega, J. Soberino García, M. Alva Bianchi, T. Pascual, A.M. Gaspar,G. Villacampa Javierre, W. Buckingham,

ESMO Open (2024)

引用0浏览0引用

49P A ctDNA tool for identifying ESR1-mutated biology in ESR1-non-mutated hormone receptor-positive (HR+) metastatic breast cancer (MBC)

I. Garcia Fructuoso, O. Martínez-Sáez, F. Pardo, M.D.R. Vega León, J. Matito,L. Pare Brunet, O. Castillo,G. Villacampa Javierre, P. Galván, J. Odegaard, P. Villagrasa Gonzalez, J. Parker,

ESMO Open (2024)

引用0浏览0引用

1MO HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer

G. Villacampa Javierre, J. Cortés,J.M. Pérez García,A. Llombart Cussac, P. Tarantino,P.F. Conte, M. Mancino, V. Guarneri, M.V. Dieci, A. Waks, F. Brasó-Maristany, T. Pascual,

ESMO Open (2024)

引用0浏览0引用

102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset

T. Pascual,G. Villacampa, F. Brasó-Maristany,L. Pare Brunet,O. Martinez Saez,J. Cortés, E.M. Ciruelos,M. Martin Jimenez, P.F. Conte, L.A. Carey, A. Fernandez-Martinez, N. Harbeck,

ESMO Open（2023）

引用0浏览0引用

3MO Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)

B. Conte, F. Brasó-Maristany,T. Pascual, F. Schettini, J. Staaf, L. Paré, M. Marín-Aguilera, O. Martínez-Sáez,A. Rodriguez Hernandez,M.J. Vidal Losada, P.F. Conte, A. Vivancos,

Annals of Oncology（2022）

引用4浏览0引用

25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial

F. Brasó-Maristany,O. Martinez Saez,L. Pare Brunet, M. Marín-Aguilera,P.F. Conte, P. Jares, V. Guarneri,T. Pascual, J.A. Puig-Butille, A. Vivancos, J. Parker,P. Villagrasa Gonzalez,

Annals of Oncology（2022）

引用0浏览0引用

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)